A sample text widget

Etiam pulvinar consectetur dolor sed malesuada. Ut convallis euismod dolor nec pretium. Nunc ut tristique massa.

Nam sodales mi vitae dolor ullamcorper et vulputate enim accumsan. Morbi orci magna, tincidunt vitae molestie nec, molestie at mi. Nulla nulla lorem, suscipit in posuere in, interdum non magna.

Perifosine to be produced by Hikma in Cooperation with Aeterna Zentaris

, a leading pharmaceutical manufacturer, and Aeterna Zentaris, late-stage oncology drug development company, have made a licensing agreement for the anti-cancer drug . Perifosine will be the first novel oncology product provided by Hikma in advanced and . Hikma‘s exclusive rights for registering and marketing the new treatment were announced at a ceremony and press conference. The agreement was signed by Mr. Mazen Darwazeh, Hikma Pharmaceuticals Executive Vice Chairman and CEO of the Middle East and North Africa (MENA) region, and Professor Juergen Engel, PhD, President and CEO of Aeterna Zentaris.

Perifosine is considered one of the most advanced oncology product used to treat colorectal cancer and multiple myeloma. This step represents Hikma‘s vision to ensure that the healthcare sector in the MENA region is as well-equipped as possible in fighting cancer. This agreement will give Hikma the right to enroll patients in clinical trials for Perifosine, as well as the possibility of generating the medication in its specialized manufacturing facilities. During its trip in developing medicines, Hikma will be the first and only company in the region that is investing in cancer medications.

Mr. Mazen Darwazah said “The agreement provides an opportunity to supply patients in the region with one of the most important products for the treatment of colorectal cancer, and multiple myeloma. Hikma Pharmaceuticals‘ goal is to equip the medical sector regionally with high quality pioneering medicinal options to reduce their dependency on a single source for treatment”. Prof. Juergen Engel stated “Hikma Pharmaceuticals has a proven track record in oncology and is the leading pharmaceutical company in the region, which is why we believe Hikma is the perfect fit for the development and commercialization of Perifosine in the region.”

VN:F [1.9.22_1171]
Rating: 0.0/10 (0 votes cast)
VN:F [1.9.22_1171]
Rating: 0 (from 0 votes)

Leave a Reply

You can use these HTML tags

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>